Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1
Rinske Drost, … , Peter Bouwman, Jos Jonkers
Rinske Drost, … , Peter Bouwman, Jos Jonkers
Published July 25, 2016
Citation Information: J Clin Invest. 2016;126(8):2903-2918. https://doi.org/10.1172/JCI70196.
View: Text | PDF
Research Article Cell biology Oncology

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1

  • Text
  • PDF
Abstract

Heterozygous germline mutations in breast cancer 1 (BRCA1) strongly predispose women to breast cancer. BRCA1 plays an important role in DNA double-strand break (DSB) repair via homologous recombination (HR), which is important for tumor suppression. Although BRCA1-deficient cells are highly sensitive to treatment with DSB-inducing agents through their HR deficiency (HRD), BRCA1-associated tumors display heterogeneous responses to platinum drugs and poly(ADP-ribose) polymerase (PARP) inhibitors in clinical trials. It is unclear whether all pathogenic BRCA1 mutations have similar effects on the response to therapy. Here, we have investigated mammary tumorigenesis and therapy sensitivity in mice carrying the Brca1185stop and Brca15382stop alleles, which respectively mimic the 2 most common BRCA1 founder mutations, BRCA1185delAG and BRCA15382insC. Both the Brca1185stop and Brca15382stop mutations predisposed animals to mammary tumors, but Brca1185stop tumors responded markedly worse to HRD-targeted therapy than did Brca15382stop tumors. Mice expressing Brca1185stop mutations also developed therapy resistance more rapidly than did mice expressing Brca15382stop. We determined that both murine Brca1185stop tumors and human BRCA1185delAG breast cancer cells expressed a really interesting new gene domain–less (RING-less) BRCA1 protein that mediated resistance to HRD-targeted therapies. Together, these results suggest that expression of RING-less BRCA1 may serve as a marker to predict poor response to DSB-inducing therapy in human cancer patients.

Authors

Rinske Drost, Kiranjit K. Dhillon, Hanneke van der Gulden, Ingrid van der Heijden, Inger Brandsma, Cristina Cruz, Dafni Chondronasiou, Marta Castroviejo-Bermejo, Ute Boon, Eva Schut, Eline van der Burg, Ellen Wientjens, Mark Pieterse, Christiaan Klijn, Sjoerd Klarenbeek, Fabricio Loayza-Puch, Ran Elkon, Liesbeth van Deemter, Sven Rottenberg, Marieke van de Ven, Dick H.W. Dekkers, Jeroen A.A. Demmers, Dik C. van Gent, Reuven Agami, Judith Balmaña, Violeta Serra, Toshiyasu Taniguchi, Peter Bouwman, Jos Jonkers

×

Figure 3

Poor olaparib response of KB1(185stop)P mouse mammary tumors.

Options: View larger image (or click on image) Download as PowerPoint
Poor olaparib response of KB1(185stop)P mouse mammary tumors.
(A) Schema...
(A) Schematic representation of olaparib treatment schedule. Tx, orthotopic transplantation of fragments from spontaneous mouse mammary tumors; t0, start of treatment at a tumor volume of 200 mm3 (100%). Mice received a daily dose of 50 mg/kg olaparib i.p. for 28 consecutive days. (B) OS curves of mice transplanted with KB1(185stop)P, KB1(5382stop)P, KB1P, or KP tumors without treatment. t50, median OS. KB1(185stop)P: t50 = 15 days, n = 4 mice; KB1(5382stop)P: t50 = 8 days, n = 6 mice; KB1P: t50 = 12 days, n = 4 mice; KP: t50 = 11 days, n = 4 mice. (C) OS curves of mice transplanted as indicated in B, after olaparib treatment. KB1(185stop)P: t50 = 26 days, n = 12 mice; KB1(5382stop)P: t50 = 52 days, n = 10 mice; KB1P: t50 = 60 days, n = 7 mice; KP: t50 = 10 days, n = 5 mice. P = 0.0012, by log-rank test for KB1(185stop)P vs. KB1(5382stop)P; P < 0.0001, by log-rank test for KB1(185stop)P vs. KB1P; P = 0.0017, log-rank test for KB1(185stop)P vs. KP; P = 0.0905 (NS), by log-rank test for KB1(5382stop)P vs. KB1P; P < 0.0001, by log-rank test for KB1(5382stop)P vs. KP; and P = 0.0003, by log-rank test for KB1P vs. KP. (D) Comparison of relative mammary tumor volumes during a 28-day treatment with olaparib. Tumor volumes are relative to the tumor volume at the start of treatment (day 0, 100% = ±200 mm3). Error bars indicate SEM.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts